

Marked Up Copy of Amended Claims

1. (Amended) A drug delivery composition for delivering a drug to the colonic region comprising a starch capsule containing the drug and wherein the starch capsule is provided with a coating such that the drug is predominantly released from the capsule in the colon and/or terminal ileum, wherein the drug is not an immunosuppressive agent which is in solution.

8. (Amended) A drug delivery composition according to [any one of the preceding claims] claim 1 wherein the coating has a thickness in the range of 80 μm to 300 μm .

9. (Amended) A drug delivery according to [any one of the preceding claims] claim 1 wherein the drug is one which acts locally in the colon.

10. (Amended) A drug delivery composition according to [any one of claims 1 to 8] claim 1 wherein the drug is for systemic delivery and systemic action.


11. (Amended) A drug delivery composition according to [any one of claims 1 to 8] claim 1 wherein the drug is a vaccine for delivery to the lymphoid tissue of the colon.

13. (Amended) A method of delivering a vaccine to the lymphoid tissue present in the colon of a human or mammal comprising orally administering a drug delivery composition comprising a starch capsule containing the vaccine and wherein the starch capsule is provided

Continuation of U.S.S.N. 08/765,347
Filed: December 27, 2000
PRELIMINARY AMENDMENT
Express Mail Label No. EL 709 420 260 US
Date of Deposit: December 27, 2000

with a coating such that the vaccine is predominantly released from the capsule in the colon
and/or terminal ileum, wherein the drug is not an immunosuppressive agent which is in solution.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: December 27, 2000

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

U.S.S.N.: Continuation of 08/765,347
Filed: December 27, 2000
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: December 27, 2000

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)